Adimmune Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Adimmune with three other
companies in this sector in TAIWAN :
sales of 1.07 billion Taiwanese Dollars [US$38.34 million]
of which 100%
was Antibody and Protein Medicine Developmen),
Syn-Tech Chem. & Pharm. Co., Ltd.
(983.79 million Taiwanese Dollars [US$35.19 million]
of which 100%
was Sales revenue), and
(806.58 million Taiwanese Dollars [US$28.85 million]
Adimmune reported sales of 1.87 billion Taiwanese Dollars (US$66.86 million)
December of 2020.
increase of 43.8%
versus 2019, when the company's sales were 1.30 billion Taiwanese Dollars .
This was the third consecutive year of growth at Adimmune.
Sales of Semi Finished Products Sales saw an increase
that was more than double the company's growth rate: sales were up
3,860.4% in 2020, from
318,000.00 Taiwanese Dollars to 12.59 million Taiwanese Dollars .
Adimmune also saw significant increases in sales in
Finished Products Sales (up 88.8% to 1.36 billion Taiwanese Dollars )
Not all segments of Adimmune experienced an increase in sales in 2020:
sales of Others Income fell 98.7% to 24,000.00 Taiwanese Dollars .
(However, this segment's sales were only a very small portion of the company's overall sales).
Adimmune also experienced decreases in sales in
Filling Service Income (down 14.0% to 496.21 million Taiwanese Dollars )